"We are very pleased to announce record fourth quarter 2022 revenue that demonstrated continued strong customer adoption and further market share gains," said David Moatazedi, President and Chief Executive Officer. "During the quarter, we continued to add customer accounts and expand our consumer loyalty program, with both metrics reaching all-time highs. This helped drive sales growth well above the projected growth rate of our industry, making Jeuveau(R) the fastest-growing neurotoxin in the U.S. for the second consecutive year. Our focus on the millennial consumer, the most rapidly-growing neurotoxin user segment, and our unique business model represents a powerful formula that gives us the confidence to project our total net revenue can reach $500 million by 2028, a compound organic growth rate of 22%."
Published first on TheFly
